Recent Financial Performance Overview
Conference call scheduled for 4:30 p.m. ET today
Key Highlights from the Latest Quarter
- Oral VK2735 to advance into Phase 3 for obesity in Q3 2026.
- Ongoing Phase 3 VANQUISH Trials for VK2735; full enrollment reached in VANQUISH-1, with VANQUISH-2 nearing completion.
- VK2735 Maintenance Dosing Study is fully enrolled; results expected in Q3 2026.
- IND filing for novel amylin agonist planned this quarter.
- Strong cash position of $706 million as of the quarter's end.
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical firm dedicated to developing groundbreaking treatments for metabolic and endocrine disorders, provided a comprehensive overview of its financial performance for the fourth quarter and the entire year of 2025. This announcement also showcased the latest updates regarding its clinical endeavors and corporate progress.
Company and Clinical Program Developments
Brian Lian, Ph.D., the CEO of Viking, emphasized, "The past year has been remarkable for Viking, characterized by significant advancements in our obesity treatment pipeline." In June, Viking commenced the Phase 3 VANQUISH studies, focusing on VK2735, a dual agonist targeting GLP-1 and GIP receptors for obesity management. As the fourth quarter concluded, the company completed recruitment for VANQUISH-1 and anticipates full enrollment of VANQUISH-2 shortly.
Advancements in the Clinical Pipeline
Viking is excited about the promising outcomes from the Phase 2 VENTURE study involving VK2735, where patients exhibited considerable weight loss - with averages reaching up to 14.7% after 13 weeks. Post an end-of-Phase 2 consultation with the FDA, the company is gearing up to transition oral VK2735 into a Phase 3 study by Q3 2026. This advancement is vital for patients looking for sustainable weight maintenance options.
Concurrently, Viking has rolled out a study assessing various dosing regimens, which aims to explore the possibility of both monthly subcutaneous and daily oral dosing options. This innovative approach could establish VK2735 as a unique dual agonist capable of offering diverse administration routes. The company's commitment to thorough research is evident, especially as they prepare to unveil significant findings in the third quarter of 2026.
Financial Highlights and Year-End Insights
During the fourth quarter of 2025, the company's research and development expenses surged to $153.5 million, attributed primarily to increased investments in clinical trials, alongside stock-based compensation and staffing costs. In contrast, general administrative expenses totaled $11.3 million, reflecting a reduction from $15.3 million in 2024.
Annual Financial Overview
For the fiscal year ending December 31, 2025, Viking reported an overall net loss of $358.5 million, or $3.19 per share, a marked increase from the $110.0 million reported in 2024. This notable escalation in losses primarily resulted from amplified research and development expenditures, countered somewhat by reduced general and administrative costs.
The company’s cash, cash equivalents, and short-term investments stood at $706 million as of December 31, 2025. Viking is confident that its strong financial foundation will enable it to pursue its critical developmental milestones in the near future.
Looking Ahead at Corporate Goals
Management has an optimistic outlook for 2026, highlighting plans for active participation in significant investor events that will facilitate discussions on the company’s forward momentum:
- Leerink Partners 2026 Global Healthcare Conference in Miami, FL, on March 8-11, 2026.
- Jefferies Biotech on the Beach Summit in Miami, FL, on March 10-11, 2026.
- Raymond James Biotech/BioPharma Conference in New York, NY, on April 14, 2026.
Frequently Asked Questions
What recent advancements has Viking Therapeutics made?
Viking Therapeutics has initiated Phase 3 trials for VK2735 and fully enrolled studies in its clinical pipeline for obesity treatments.
What is VK2735's role in Viking's pipeline?
VK2735 is a dual agonist targeting GLP-1 and GIP receptors, being researched for its efficacy in treating obesity.
When is Viking planning to advance oral VK2735 into Phase 3?
The company aims to move oral VK2735 into Phase 3 trials by Q3 2026 following positive Phase 2 results.
What are Viking's current financial standings?
Viking reported a strong cash position of $706 million as of December 31, 2025, supporting its future endeavors.
What upcoming investor events will Viking participate in?
Viking will be attending the Leerink Partners Global Healthcare Conference and other significant investor events in 2026.
